3SCHILLER JH,HARRINGTON D,BELANI CP,et al.Comparison of four chemot herapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346:92-98.
4KURIHARA M,AOKI K,HISAMICHI S.Cancer mortality statistics in the world,1950-1985[M].Nagoya:Nagoya University Press,1989:68.
5MAGRATH I,LITVAK J.Cancer in developing countries:opportunity and challenge[J].J Natl Cancer Inst,1993,85:862.
6GROVER S,QUINN MA,WEIDEMAN P,et al.Screening for ovarian cancer using serum CA-125 and vaginal examination report on 2550 females[J].Int J Gynecol Cancer,1995,5 (4):291-295.
7SALGIA R,HARPOLE D,HERNDON JE,et al.Role of serum tumor markers CA-125 and CEA in non-small-cell lung cancer[J].Anti cancer Res,2001,21 (2B):1241-1246.
8ANDO S,KIMURA H,IWAI N,et al.Optimal combination of seven tumour markers in prediction of advanccd at first cxamination ofpaticnts with non-small-ccll lung cancer[J].Anticancer Rcs,2001,21 (4B):3085-3092.
9HATZAKIS KD,FROUDARAKISM E,BOUROSD,et al.Prognostic value of serumtumor markers in patients with lung cancer[J].Respiration,2002,69 (1):25-29.
10ANDO S,KIMURA H,IWAI N,et al.Optimal combination of seven tumor markers in prediction of advanced at first examination of patients with non-small cell lung cancer[J].Anticancer Res,2001,21(4B):3085-3092.
